FAACT's Roundtable

Ep. 204: Exciting Updates from AAAAI 2024

March 02, 2024 Shahzad Mustafa Season 4 Episode 204
FAACT's Roundtable
Ep. 204: Exciting Updates from AAAAI 2024
Show Notes

Learn about ground-breaking news and updates from the recent American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting held this February in Washington, D.C. In lay relatable terms, FAACT’s Medical Advisory Board Chair, Dr. Shahzad Mustafa, discusses the approval of Xolair and what it means for the food allergy community. He also shares his thoughts regarding treatments that are on-the-horizon for anaphylaxis from ARS Pharma, Bryn Pharma, Aquestive, DBV Technologies, and Blueprint Medicines.

Resources to keep you in the know:

You can also find FAACT’s Roundtable Podcast on Apple Podcast, Spotify, iHeart Radio, Podcast Chaser, Deezer, Tune-In, Alexa, and Listen Notes or wherever you listen to podcasts.

Follow us on Facebook, X (formerly known as Twitter), Instagram, Threads, LinkedIn, Pinterest, TikTok, and

Thanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!